MPS II Immunophenotyping
NCT04976231 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6
Last updated 2024-09-19
Summary
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.
Conditions
- MPS II
- Mucopolysaccharidosis II
- Hunter Syndrome
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Priya Kishnani, MD · Duke University
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-01
- Primary Completion
- 2024-04-26
- Completion
- 2024-04-26
Countries
- United States
Study Locations
More Related Trials
-
Individual Patient Compassionate Use of Mirdametinib
NCT05028166 ·Status: AVAILABLE
-
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT03962543 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Mirdametinib in Histiocytic Disorders
NCT06153173 ·Status: RECRUITING ·Phase: PHASE2
-
Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy
NCT03936894 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959 ·Status: RECRUITING
-
Daratumumab in HLA Desensitization Prior to Transplantation
NCT05300451 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study
NCT02271165 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Abatacept in Juvenile Dermatomyositis
NCT02594735 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
NCT00230334 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
NCT02990286 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
NCT02576145 ·Status: COMPLETED ·Phase: PHASE4
-
Novel Testing Procedures
NCT01793506 ·Status: WITHDRAWN
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
NCT05695261 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers
NCT03837093 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
NCT00811590 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children
NCT02377427 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
NCT00266565 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Baked Milk Oral Immunotherapy for Cow's Milk Allergy
NCT03462030 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of MSB11455 in Healthy Participants
NCT03251339 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Tolerance Study With Aldurazyme® (Laronidase)
NCT00741338 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
NCT00795574 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
NCT02185651 ·Status: TERMINATED ·Phase: PHASE1
-
Midostaurin in Indolent Systemic Mastocytosis
NCT01920204 ·Status: UNKNOWN ·Phase: PHASE2